Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers
Executive Summary
Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside Medicare's reimbursement bundle for end-stage renal disease.
You may also be interested in...
US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best
Recent developments in US federal government regulation of prescription drug pricing and reimbursement.
Phase III Roxadustat ALPS Data Positive For New Class Of Anemia Therapies
Positive top-line data from the ALPS study confirms the efficacy and safety of roxadustat, a Phase III-stage product which could be the first a new class of orally active agents with potential in the treatment of anemia associated with chronic kidney disease.
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: